CD8A and prostate cancer: In agreement with the fact that the AR is a major driver of prostate cancer and is the therapeutic target of ENZ, CIBERSORT analysis showed that AR expression levels negatively correlated with CD8+ T cell infiltration in The Cancer Genome Atlas (TCGA) prostate cancer samples (Figure 3A).